In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.
무작위 임상시험
0/5 보강
APA
Gouveia A, Dayes I, Tsakiridis T (2025). In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.. The Prostate, 85(15), 1451-1452. https://doi.org/10.1002/pros.70023
MLA
Gouveia A, et al.. "In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.." The Prostate, vol. 85, no. 15, 2025, pp. 1451-1452.
PMID
40719443 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.
- Role of Cytokines in Oligometastatic Non-Small-Cell Lung Cancer Treated with Stereotactic Radiation Therapy: An Observational Pilot Study.
- SIRT Combined with Targeted Therapy and Immunotherapy Achieves Sustained Complete Remission in Advanced Hepatocellular Carcinoma: A Case Report.
- Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know?
- Predicting Stereotactic Body Radiation Therapy Response Using an AI-Based Tumor Vessel Biomarker.